TW202304905A - 抑制ｎｌｒｐ３的化合物及其用途 - Google Patents

抑制ｎｌｒｐ３的化合物及其用途 Download PDF

Info

Publication number
TW202304905A
TW202304905A TW111113264A TW111113264A TW202304905A TW 202304905 A TW202304905 A TW 202304905A TW 111113264 A TW111113264 A TW 111113264A TW 111113264 A TW111113264 A TW 111113264A TW 202304905 A TW202304905 A TW 202304905A
Authority
TW
Taiwan
Prior art keywords
alkyl
aryl
cycloalkyl
compound
membered heteroaryl
Prior art date
Application number
TW111113264A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬妮 杜瑞奇
傑森 布奇
米格爾 聖安格
阿曼丁 切夫森
亞歷山大 科特
拉姆賽 貝弗瑞
史蒂芬 賽伯特
Original Assignee
美商凡特斯治療美國公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商凡特斯治療美國公司 filed Critical 美商凡特斯治療美國公司
Publication of TW202304905A publication Critical patent/TW202304905A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW111113264A 2021-04-07 2022-04-07 抑制ｎｌｒｐ３的化合物及其用途 TW202304905A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163171932P 2021-04-07 2021-04-07
US63/171,932 2021-04-07
US17/528,928 2021-11-17
US17/528,928 US11319319B1 (en) 2021-04-07 2021-11-17 Compounds for inhibiting NLRP3 and uses thereof

Publications (1)

Publication Number Publication Date
TW202304905A true TW202304905A (zh) 2023-02-01

Family

ID=81385286

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111113264A TW202304905A (zh) 2021-04-07 2022-04-07 抑制ｎｌｒｐ３的化合物及其用途

Country Status (15)

Country Link
US (10) US11319319B1 (enExample)
EP (3) EP4331668A3 (enExample)
JP (2) JP7620120B2 (enExample)
KR (1) KR20230167394A (enExample)
CN (2) CN117500792A (enExample)
AU (3) AU2022256052B2 (enExample)
BR (1) BR112023020483A2 (enExample)
CA (1) CA3214676A1 (enExample)
CL (2) CL2023002973A1 (enExample)
CO (1) CO2023013356A2 (enExample)
IL (2) IL307303A (enExample)
MX (2) MX2023011576A (enExample)
PE (1) PE20240765A1 (enExample)
TW (1) TW202304905A (enExample)
WO (1) WO2022216971A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CA3216026A1 (en) 2021-06-04 2022-12-08 F. Hoffmann-La Roche Ag Triazine derivatives and their use in the treatment of cancer
WO2022253326A1 (zh) * 2021-06-05 2022-12-08 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
EP4363406B1 (en) * 2021-07-02 2025-09-10 Astrazeneca AB Nlrp3 inflammasome inhibitors
AU2022312986A1 (en) 2021-07-21 2024-03-07 Nico Therapeutics, Inc. Annulated pyridazine compound
EP4392414A1 (en) * 2021-08-25 2024-07-03 PTC Therapeutics, Inc. Inhibitors of nlrp3
US20240391881A1 (en) * 2021-09-30 2024-11-28 Origiant Pharmaceutical Co., Ltd. Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
WO2023066377A1 (zh) * 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
EP4499638A1 (en) * 2022-03-25 2025-02-05 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives
EP4499646A1 (en) * 2022-03-31 2025-02-05 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
KR20250036233A (ko) * 2022-07-14 2025-03-13 에이씨 이뮨 에스에이 Nlrp3 인플라마좀 경로의 조절제로서의 피롤로트리아진 및 이미다조트리아진 유도체
EP4590672A1 (en) * 2022-09-23 2025-07-30 Merck Sharp & Dohme LLC Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
JP2025023868A (ja) * 2022-09-23 2025-02-17 メルク・シャープ・アンド・ドーム・エルエルシー Ｎｏｄ様受容体タンパク質３の阻害剤として有用なフタラジン誘導体
TW202432551A (zh) 2022-10-26 2024-08-16 日商安斯泰來製藥股份有限公司 稠環嗒嗪衍生物
TW202419449A (zh) * 2022-10-31 2024-05-16 美商凡特斯治療美國公司 可用作ｎｌｒｐ３抑制劑之橋接雙環雜環烷基吡啶并－〔３，４－ｄ〕噠嗪胺衍生物
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2023371859A1 (en) * 2022-11-04 2025-06-12 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and use thereof
CN120225506A (zh) * 2022-11-25 2025-06-27 成都赜灵生物医药科技有限公司 桥环并哒嗪类化合物及其用途
WO2024137319A1 (en) * 2022-12-19 2024-06-27 Merck Sharp & Dohme Llc 6,6 bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
CN120379995A (zh) * 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
UY40587A (es) 2022-12-28 2024-07-31 Astrazeneca Ab Inhibidores del inflamasoma nlrp3
EP4644380A1 (en) * 2022-12-28 2025-11-05 Changchun Genescience Pharmaceutical Co., Ltd. Pyridazine nlrp3 inhibitor compound, pharmaceutical composition, and preparation method therefor and use thereof
EP4642763A1 (en) 2022-12-28 2025-11-05 Astrazeneca AB Crystalline forms of nlrp3 inflammasome inhibitors, chemical processes and chemical compounds
KR20250136883A (ko) 2023-01-24 2025-09-16 다이이찌 산쿄 가부시키가이샤 치환 벤젠 화합물
EP4658640A1 (en) 2023-01-31 2025-12-10 Janssen Pharmaceutica NV Pyridin-2(1h)-ones and pyrimidin-4(3h)-ones as nlrp3 inhibitors
WO2024160694A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv [1,2,4]TRIAZOLO[4,3-a]PYRIDINES AND [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS NLRP3 INHIBITORS
AU2024214952A1 (en) 2023-01-31 2025-09-11 Janssen Pharmaceutica Nv 2-(pyridazin-3-yl)-5-(trifluoromethyl)phenols as nlrp3 inhibitors
KR20250134147A (ko) 2023-01-31 2025-09-09 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 피롤로[1,2-d][1,2,4]트리아진 및 피라졸로[1,5-d] [1,2,4]트리아진
AU2024213537A1 (en) 2023-01-31 2025-09-11 Janssen Pharmaceutica Nv Imidazo[1,2-d][1,2,4]triazines as nlrp3 inhibitors
WO2024169858A1 (zh) * 2023-02-17 2024-08-22 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途
WO2024217462A1 (zh) * 2023-04-18 2024-10-24 南京明德新药研发有限公司 五氟化硫取代的芳环化合物及其应用
AR132817A1 (es) 2023-06-02 2025-07-30 Merck Sharp & Dohme Llc Heterociclos bicíclicos 5,6 insaturados útiles como inhibidores de la proteína receptora 3 similar a nod
WO2025006681A2 (en) * 2023-06-27 2025-01-02 Viva Star Biosciences (Us) Inc. Substituted pyridazine compounds as inhibitors of nlrp3 activity and therapeutic uses thereof
TW202506132A (zh) * 2023-08-11 2025-02-16 大陸商藥捷安康(南京)科技股份有限公司 Nlrp3炎症小體抑制劑及其應用
CN117143027B (zh) * 2023-08-31 2024-12-20 四川大学 3-苄氧基-6-羟苯基哒嗪类化合物及其制备方法和用途
WO2025059069A1 (en) * 2023-09-12 2025-03-20 Zomagen Biosciences Ltd Nlrp3 modulators
WO2025059481A1 (en) * 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Solid forms of an nlrp3 inhibitor and uses thereof
JP2025083323A (ja) * 2023-11-20 2025-05-30 ヴェンタス・セラピューティクス・ユー・エス・インコーポレイテッド Ｎｌｒｐ３を阻害するための５－クロロ－２－（４－（（２－ヒドロキシ－２－メチルプロピル）アミノ）ピリド［３，４－ｄ］ピリダジン－１－イル）フェノールの固体遊離塩基形態およびその使用
WO2025128777A1 (en) 2023-12-14 2025-06-19 Merck Sharp & Dohme Llc Indazole derivatives useful as inhibitors of nod-like receptor protein 3
TW202532066A (zh) 2023-12-14 2025-08-16 美商默沙東有限責任公司 作為nod樣受體蛋白3抑制劑之氮雜吲唑衍生物
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
GB1303061A (enExample) * 1969-05-03 1973-01-17
GB2063249A (en) * 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU3752589A (en) 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
JPH03284669A (ja) * 1990-03-30 1991-12-16 Mitsubishi Kasei Corp ４―フェニルフタラジン誘導体
DE69105572T2 (de) 1990-03-30 1995-05-11 Mitsubishi Chem Ind 4-Phenylphthalazin-Derivate.
TW279162B (enExample) * 1991-09-26 1996-06-21 Mitsubishi Chem Corp
WO1993015058A1 (en) 1992-01-23 1993-08-05 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
US5565472A (en) 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
DE4417746A1 (de) 1994-05-20 1995-11-23 Bayer Ag Neue Farbstoffe zum Massefärben von Kunststoffen
DE69533057T2 (de) * 1994-08-09 2005-06-16 Eisai Co., Ltd. Kondensierte pyridazinverbindungen
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US6288064B1 (en) 1996-08-20 2001-09-11 Eisai Co., Ltd. Remedy for erection failure comprising fused pyridazine compound
US20030124053A1 (en) 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
WO1998027066A1 (en) 1996-12-18 1998-06-25 Neurogen Corporation Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
US6486158B1 (en) 1998-08-14 2002-11-26 Cell Pathways, Inc. [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
AU765128B2 (en) 1999-03-22 2003-09-11 Bristol-Myers Squibb Company Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
IL161836A0 (en) 2001-11-30 2005-11-20 Pfizer Prod Inc Aryl fused azapolycyclic compounds
WO2004099158A1 (en) 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Monocyclic diazodioxide based bcl-2 protein antagonists
WO2005016000A1 (en) 2003-08-05 2005-02-24 Avalon Pharmaceuticals Derivatives of cyclic quinone and uses thereof
US7087621B2 (en) 2003-09-05 2006-08-08 Bristol-Myers Squibb Company Benzo- and azabenzodithiazole compounds
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
CA2564996A1 (en) 2004-05-08 2006-01-12 Taeyoung Yoon 3-aryl-5,6-disubstituted pyridazines
KR101179382B1 (ko) 2004-06-09 2012-09-03 에릭 엠. 카레이라 모노포스핀 화합물, 그의 전이 금속 착체 및 상기 착체를비대칭 촉매로서 사용하는 광학 활성 화합물의 제조 방법
US20060156485A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
KR20080048550A (ko) 2005-09-23 2008-06-02 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
FR2891828B1 (fr) 2005-10-12 2007-12-21 Sanofi Aventis Sa Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique
WO2007056281A2 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
US20090239896A1 (en) 2005-11-03 2009-09-24 Han-Ting Chang Azaindole compounds and use thereof as phospholipase-a2 inhibitors
US20070179123A1 (en) 2005-11-08 2007-08-02 Chiang Peter K Methods and compositions for treating diseases associated with pathogenic proteins
JP2009120486A (ja) * 2005-12-05 2009-06-04 Mitsubishi Pharma Corp 核内オーファン受容体の新規活性化剤及びその用途
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
CA2637658C (en) 2006-01-23 2012-07-17 Amgen Inc. Aurora kinase modulators and method of use
CN101426779B (zh) 2006-02-16 2013-08-21 先正达参股股份有限公司 含有二环双酰胺结构的农药
US20090318476A1 (en) 2006-08-09 2009-12-24 Merck Frosst Canada Ltd. Azacycloalkane Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
BRPI0810653A2 (pt) 2007-04-19 2014-11-04 Novartis Ag Derivados de ácido nicotínico como moduladores do receptor metabotrópico de glutamato-5.
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US9023490B2 (en) 2007-06-15 2015-05-05 Versitech Limited Extended pi-conjugated platinum (II) complexes
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
US20090082358A1 (en) 2007-09-20 2009-03-26 Nobuko Nishimura Vanilloid receptor ligands and their use in treatments
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2011507848A (ja) 2007-12-21 2011-03-10 ザ スクリプス リサーチ インスティチュート Ｒｈｏキナーゼインヒビターとしてのベンゾピランおよびアナログ
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
CA2725398A1 (en) 2008-04-11 2009-10-15 The Regents Of The University Of Michigan Heteroaryl-substituted bicyclic smac mimetics and the uses thereof
EP2291078A4 (en) 2008-05-15 2011-08-24 Merck Sharp & Dohme OXAZOLBENZIMIDAZOLDERIVATE
CA2728018C (en) 2008-06-16 2016-10-11 Merck Patent Gmbh Quinoxalinedione derivatives
CN102076653A (zh) 2008-06-25 2011-05-25 住友化学株式会社 用于制备光学活性胺化合物的方法
NZ590500A (en) 2008-08-16 2012-06-29 Genentech Inc Azaindole inhibitors of iap
CA2738254A1 (en) 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
WO2010101949A1 (en) 2009-03-02 2010-09-10 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2414353A1 (en) 2009-04-01 2012-02-08 Basf Se Isoxazoline compounds for combating invertebrate pests
US9198907B2 (en) 2009-04-06 2015-12-01 Ptc Therapeutics, Inc. Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
WO2010117935A1 (en) 2009-04-06 2010-10-14 Schering Corporation Compounds and methods for antiviral treatment
EP2445886B1 (en) 2009-06-25 2016-03-30 Amgen, Inc 4-aminoquinoline derivatives as pi3k inhibitors
EP2459543B1 (en) 2009-07-29 2017-08-30 Karus Therapeutics Limited Benzo[e][1,3]oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
WO2011075607A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US8791113B2 (en) 2010-06-28 2014-07-29 Merck Patent Gmbh 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
CA2803620A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their uses
US20130165440A1 (en) 2010-09-14 2013-06-27 Exelixis, Inc. JAK1 Inhibitors
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP6030640B2 (ja) 2011-05-18 2016-11-24 シンジェンタ パーティシペーションズ アーゲー アリールチオアセトアミド誘導体をベースとする殺虫化合物
US8912202B2 (en) 2011-08-08 2014-12-16 Merck Patent Gmbh N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
WO2013026939A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Methods for the control of termites and ants
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
JP5976206B2 (ja) 2012-05-22 2016-08-23 イーライ リリー アンド カンパニー 神経機能障害を検出するための造影剤
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
WO2014079935A1 (en) 2012-11-21 2014-05-30 Syngenta Participations Ag Insecticidal compounds based on arylthioacetamide derivatives
WO2014079941A1 (en) 2012-11-21 2014-05-30 Syngenta Participations Ag Insecticidal compounds based on n-(arylsulfanylmethyl) carboxamide derivatives
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014086737A1 (de) 2012-12-06 2014-06-12 Bayer Cropscience Ag Kondensierte 2-pyridon-3-carboxamide und ihre verwendung als herbizide
TW201439060A (zh) 2013-02-27 2014-10-16 Sunshine Lake Pharma Co Ltd 作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
AR097631A1 (es) 2013-09-16 2016-04-06 Bayer Pharma AG Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
LT3126330T (lt) 2014-04-04 2019-04-25 Pfizer Inc. Bicikliniai kondensuoti heteroarilo arba arilo junginiai, ir jų panaudojimas kaip irak4 inhibitorių
CN103992311B (zh) * 2014-06-20 2017-01-25 东南大学 Hedgehog信号通路抑制剂
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
KR20170117030A (ko) 2014-12-22 2017-10-20 아카나 테라퓨틱스, 엘티디. 질환의 치료를 위한 융합된 비시클릭 화합물
US20180093956A1 (en) 2015-02-06 2018-04-05 Abbvie Inc. Substituted phthalazines
PT3578547T (pt) 2015-02-16 2021-06-22 The Provost Fellows Found Scholars And Other Members Of Board Of College Of Holy And Undivided Trini Sulfonilureias e compostos relacionados e uso dos mesmos
KR102488323B1 (ko) 2015-12-10 2023-01-12 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
EA037302B9 (ru) 2016-02-12 2021-04-09 Фармаксис Лтд. Ингибиторы лизилоксидаз, представляющие собой индольные и азаиндольные производные галогеналлиламина, и их применения
HK1257569A1 (zh) 2016-02-16 2019-10-25 The University Of Queensland 磺醯脲和相关化合物及其用途
WO2017144341A1 (de) 2016-02-23 2017-08-31 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
EP3236267B1 (en) 2016-04-18 2021-09-08 Roche Diagnostics GmbH Decapper and apparatus
JP7050751B2 (ja) 2016-04-18 2022-04-08 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
MA44734A (fr) 2016-04-18 2021-05-19 Novartis Ag Composés et compositions destinés au traitement d'états associés à une activité de nlrp
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
WO2018031680A1 (en) 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
US10947241B2 (en) * 2016-10-28 2021-03-16 Seoul National University Hospital Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
KR102747905B1 (ko) 2017-01-31 2024-12-31 아비나스 오퍼레이션스, 인코포레이티드 세레블론 리간드 및 이를 포함하는 이작용성 화합물
WO2018172925A1 (en) 2017-03-23 2018-09-27 Vitas Pharma Research Pvt Ltd Inhibitors of dna gyrase for treatment of bacterial infections
KR20180108426A (ko) 2017-03-24 2018-10-04 희성소재 (주) 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
WO2018174678A1 (ko) 2017-03-24 2018-09-27 희성소재(주) 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
WO2018221433A1 (ja) 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
EP3553049B1 (en) 2017-07-20 2022-01-19 LG Chem, Ltd. Compound and organic light-emitting diode comprising same
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
EP3672952B1 (en) 2017-08-21 2022-12-14 Merck Patent GmbH Benzimidazole derivatives as adenosine receptor antagonists
CN110526898A (zh) 2018-05-25 2019-12-03 北京诺诚健华医药科技有限公司 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
WO2020021015A1 (en) 2018-07-26 2020-01-30 Esteve Pharmaceuticals, S.A. New imidazopyridine derivatives for treating pain and pain related conditions
US12453279B2 (en) 2018-08-22 2025-10-21 Universal Display Corporation Organic electroluminescent materials and devices
JP7682096B2 (ja) 2019-02-04 2025-05-23 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
KR102721075B1 (ko) 2019-02-15 2024-10-24 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
UY38687A (es) * 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
AR121669A1 (es) * 2020-03-27 2022-06-29 Astellas Pharma Inc Compuesto de piridazina sustituida
CN115667225A (zh) 2020-05-28 2023-01-31 詹森药业有限公司 化合物
AU2021286560A1 (en) 2020-06-09 2023-02-02 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
CN116390914A (zh) 2020-12-25 2023-07-04 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
JP7707310B2 (ja) 2021-02-08 2025-07-14 メッドシャイン ディスカバリー インコーポレイテッド 置換されたピリダジンフェノール系誘導体
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
KR20230167071A (ko) 2021-04-07 2023-12-07 포르마 세라퓨틱스 인크. 유비퀴틴-특이적 프로테아제 1 (usp1)의 억제
MX2023012795A (es) 2021-04-28 2023-11-08 Astellas Pharma Inc Compuesto de triazina sustituida.
WO2022229315A1 (en) 2021-04-29 2022-11-03 Janssen Pharmaceutica Nv Phthalazinone derivatives as nlrp3 inflammasome inhibitors
FI4337652T3 (fi) 2021-05-12 2025-06-20 Hoffmann La Roche NLRP3:n estäjiä
CA3216026A1 (en) 2021-06-04 2022-12-08 F. Hoffmann-La Roche Ag Triazine derivatives and their use in the treatment of cancer
WO2022253326A1 (zh) 2021-06-05 2022-12-08 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
EP4362946A4 (en) 2021-06-29 2025-05-21 Zomagen Biosciences Ltd Nlrp3 modulators
EP4363406B1 (en) 2021-07-02 2025-09-10 Astrazeneca AB Nlrp3 inflammasome inhibitors
EP4366831A4 (en) 2021-07-09 2025-06-11 Aligos Therapeutics, Inc. ANTI-VIRAL COMPOUNDS
AU2022312986A1 (en) 2021-07-21 2024-03-07 Nico Therapeutics, Inc. Annulated pyridazine compound
EP4392414A1 (en) 2021-08-25 2024-07-03 PTC Therapeutics, Inc. Inhibitors of nlrp3
WO2023028536A1 (en) 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
CA3226855A1 (en) 2021-08-25 2023-03-02 Zydus Lifesciences Limited Treatment for neuroinflammatory disorders
US20240391881A1 (en) 2021-09-30 2024-11-28 Origiant Pharmaceutical Co., Ltd. Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
EP4419532A1 (en) 2021-10-19 2024-08-28 F. Hoffmann-La Roche AG Fused bicyclic heteroaryl compounds useful as nlrp3 inhibitors
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
WO2023088856A1 (en) 2021-11-17 2023-05-25 F. Hoffmann-La Roche Ag Heterocyclic nlrp3 inhibitors
WO2023088987A1 (en) 2021-11-19 2023-05-25 F. Hoffmann-La Roche Ag Pyridazine derivatives as inhibitors of nlrp3
US20250074888A1 (en) 2021-12-29 2025-03-06 Neumora Therapeutics, Inc. Pyridazine derivatives as modulators of nlrp3 inflammasome and related methods
EP4461729A1 (en) 2022-01-07 2024-11-13 Transthera Sciences (Nanjing), Inc. Antigen binding protein targeting msln and use thereof
CN116726020A (zh) 2022-03-08 2023-09-12 上海拓界生物医药科技有限公司 一类含哒嗪的化合物的药物组合物及其医药用途
WO2023178099A1 (en) 2022-03-15 2023-09-21 Zomagen Biosciences Ltd Nlrp3 modulators
EP4499638A1 (en) 2022-03-25 2025-02-05 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives
EP4499646A1 (en) 2022-03-31 2025-02-05 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
CN116969920A (zh) 2022-04-29 2023-10-31 上海辉启生物医药科技有限公司 稠合哒嗪衍生物及其制备方法与医药用途
CA3251149A1 (en) 2022-05-13 2023-11-16 Neumora Therapeutics, Inc. NLRP3 INFLAMMASOME MODULATORS, ASSOCIATED PRODUCTS AND PROCESSES
CN119300833A (zh) 2022-06-03 2025-01-10 豪夫迈·罗氏有限公司 新颖化合物
WO2024006559A1 (en) 2022-07-01 2024-01-04 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
KR20250036233A (ko) 2022-07-14 2025-03-13 에이씨 이뮨 에스에이 Nlrp3 인플라마좀 경로의 조절제로서의 피롤로트리아진 및 이미다조트리아진 유도체
CN119546599A (zh) 2022-07-14 2025-02-28 南京明德新药研发有限公司 氘取代的哒嗪苯并噻吩化合物及其应用
JP2025523930A (ja) 2022-07-21 2025-07-25 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害剤
CA3261365A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa NEW COMPOUNDS
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
TW202417456A (zh) 2022-08-10 2024-05-01 日商武田藥品工業股份有限公司 雜環化合物
CN116789674B (zh) 2022-08-24 2024-05-24 杭州高光制药有限公司 Nlrp3炎性小体抑制剂
EP4590672A1 (en) 2022-09-23 2025-07-30 Merck Sharp & Dohme LLC Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
TW202432551A (zh) 2022-10-26 2024-08-16 日商安斯泰來製藥股份有限公司 稠環嗒嗪衍生物
TW202419449A (zh) 2022-10-31 2024-05-16 美商凡特斯治療美國公司 可用作ｎｌｒｐ３抑制劑之橋接雙環雜環烷基吡啶并－〔３，４－ｄ〕噠嗪胺衍生物
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2024097598A1 (en) 2022-11-02 2024-05-10 Merck Sharp & Dohme Llc Triazines useful as inhibitors of nod-like receptor protein 3
AU2023371859A1 (en) 2022-11-04 2025-06-12 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and use thereof
WO2024094150A1 (en) 2022-11-04 2024-05-10 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
WO2024099992A1 (en) 2022-11-09 2024-05-16 F. Hoffmann-La Roche Ag Triazinone derivatives as nlrp3 inhibitors
AR130983A1 (es) 2022-11-09 2025-02-05 Hoffmann La Roche Derivados de triazinona inhibidores de nlrp3
EP4615830A1 (en) 2022-11-09 2025-09-17 F. Hoffmann-La Roche AG Triazinone derivatives as nlrp3 inhibitors
CN118056822A (zh) 2022-11-18 2024-05-21 正大天晴药业集团股份有限公司 一种哒嗪并环化合物及其用途
CN120225506A (zh) 2022-11-25 2025-06-27 成都赜灵生物医药科技有限公司 桥环并哒嗪类化合物及其用途
JP2025540202A (ja) 2022-12-07 2025-12-11 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害のモジュレーターとしての新規化合物
WO2024121184A1 (en) 2022-12-08 2024-06-13 F. Hoffmann-La Roche Ag Inhibitors of nlrp3
WO2024137319A1 (en) 2022-12-19 2024-06-27 Merck Sharp & Dohme Llc 6,6 bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
WO2024138045A1 (en) 2022-12-23 2024-06-27 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
CN120379995A (zh) 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
UY40587A (es) 2022-12-28 2024-07-31 Astrazeneca Ab Inhibidores del inflamasoma nlrp3
EP4644380A1 (en) 2022-12-28 2025-11-05 Changchun Genescience Pharmaceutical Co., Ltd. Pyridazine nlrp3 inhibitor compound, pharmaceutical composition, and preparation method therefor and use thereof
CN120826402A (zh) 2022-12-30 2025-10-21 Ptc医疗公司 作为nlrp3抑制剂的杂环和杂芳基化合物
WO2024148029A2 (en) 2023-01-03 2024-07-11 Kodiak Sciences Inc. Organic compounds as nlrp3 inhibitors
KR20250134147A (ko) 2023-01-31 2025-09-09 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 피롤로[1,2-d][1,2,4]트리아진 및 피라졸로[1,5-d] [1,2,4]트리아진
EP4658640A1 (en) 2023-01-31 2025-12-10 Janssen Pharmaceutica NV Pyridin-2(1h)-ones and pyrimidin-4(3h)-ones as nlrp3 inhibitors
AU2024213537A1 (en) 2023-01-31 2025-09-11 Janssen Pharmaceutica Nv Imidazo[1,2-d][1,2,4]triazines as nlrp3 inhibitors
WO2024160694A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv [1,2,4]TRIAZOLO[4,3-a]PYRIDINES AND [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS NLRP3 INHIBITORS
AU2024214952A1 (en) 2023-01-31 2025-09-11 Janssen Pharmaceutica Nv 2-(pyridazin-3-yl)-5-(trifluoromethyl)phenols as nlrp3 inhibitors

Also Published As

Publication number Publication date
IL307303A (en) 2023-11-01
CN117510495A (zh) 2024-02-06
US11319319B1 (en) 2022-05-03
US20220340567A1 (en) 2022-10-27
AU2025213656A1 (en) 2025-08-28
JP7620120B2 (ja) 2025-01-22
US12410167B2 (en) 2025-09-09
US12281112B2 (en) 2025-04-22
CO2023013356A2 (es) 2023-10-30
CL2024001964A1 (es) 2024-12-06
EP4537900A2 (en) 2025-04-16
PE20240765A1 (es) 2024-04-17
US20240199606A1 (en) 2024-06-20
EP4320102A1 (en) 2024-02-14
MX2023011576A (es) 2023-11-09
AU2022256052A1 (en) 2023-11-16
JP2024514837A (ja) 2024-04-03
KR20230167394A (ko) 2023-12-08
IL308378A (en) 2024-01-01
US20240174668A1 (en) 2024-05-30
US12351578B2 (en) 2025-07-08
MX2024000820A (es) 2024-02-06
US20240158396A1 (en) 2024-05-16
WO2022216971A9 (en) 2022-12-08
US20240360128A1 (en) 2024-10-31
BR112023020483A2 (pt) 2023-11-21
US20240360129A1 (en) 2024-10-31
TW202330522A (zh) 2023-08-01
EP4537900A3 (en) 2025-07-16
AU2023263450C1 (en) 2025-10-30
US20230159526A1 (en) 2023-05-25
AU2022256052B2 (en) 2025-06-05
WO2022216971A1 (en) 2022-10-13
AU2023263450A1 (en) 2023-11-23
US12312350B2 (en) 2025-05-27
CN117500792A (zh) 2024-02-02
AU2023263450B2 (en) 2025-04-17
CL2023002973A1 (es) 2024-03-08
US20250250270A1 (en) 2025-08-07
EP4331668A3 (en) 2024-06-05
EP4331668A2 (en) 2024-03-06
US20240368160A1 (en) 2024-11-07
CA3214676A1 (en) 2022-10-13
US12441728B2 (en) 2025-10-14
JP2024050527A (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
TW202304905A (zh) 抑制ｎｌｒｐ３的化合物及其用途
TW202345836A (zh) 可用作ＮＬＲＰ３衍生物之吡啶并－〔３，４－ｄ〕噠嗪胺衍生物
US12312351B2 (en) Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
HK40100030A (en) Compounds for inhibiting nlrp3 and uses thereof
KR20230157535A (ko) Nlrp3을 저해하기 위한 피리다진 화합물
BR122024000756A2 (pt) Compostos inibidores de nlrp3, derivado isotópico dos mesmos, composição farmacêutica que compreende os mesmos, bem como uso dos ditos compostos para tratar ou prevenir uma doença ou distúrbio relacionado a nlrp3